ctDNA-MRD Guided Escalation of Ivonescimab and Docetaxel in Advanced NSCLC With Long-Term Responses to First-line Immunotherapy (CR1STAL-Adaptive)
Clinical trial NCT06951646 · RECRUITING
Trial details
- NCT number
- NCT06951646
- Sponsor
- Second Xiangya Hospital of Central South University
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2026-03-10
- Primary completion
- 2028-07-01
- Enrollment
- 70
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.